Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Receivables (2016 - 2025)

Historic Change in Receivables for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to -$81.6 million.

  • United Therapeutics' Change in Receivables fell 25968.69% to -$81.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.1 million, marking a year-over-year decrease of 15300.48%. This contributed to the annual value of $400000.0 for FY2024, which is 9931.62% down from last year.
  • Latest data reveals that United Therapeutics reported Change in Receivables of -$81.6 million as of Q3 2025, which was down 25968.69% from $57.3 million recorded in Q2 2025.
  • United Therapeutics' 5-year Change in Receivables high stood at $138.1 million for Q2 2023, and its period low was -$85.9 million during Q1 2023.
  • For the 5-year period, United Therapeutics' Change in Receivables averaged around $7.4 million, with its median value being $2.8 million (2022).
  • Per our database at Business Quant, United Therapeutics' Change in Receivables crashed by 85882.35% in 2021 and then soared by 483214.29% in 2023.
  • United Therapeutics' Change in Receivables (Quarter) stood at -$14.1 million in 2021, then increased by 19.86% to -$11.3 million in 2022, then skyrocketed by 279.65% to $20.3 million in 2023, then plummeted by 407.88% to -$62.5 million in 2024, then plummeted by 30.56% to -$81.6 million in 2025.
  • Its Change in Receivables was -$81.6 million in Q3 2025, compared to $57.3 million in Q2 2025 and $42.7 million in Q1 2025.